Dr. Boughey on Surgery in Patients With HER2+ Breast Cancer

Judy C. Boughey, MD
Published: Monday, Mar 28, 2016



Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.

There is not usually a difference in surgery among patients with differing subtypes of breast cancer, Boughey explains, as most surgical resections are based on the relationship between tumor size and breast size, extent of disease in the lymph nodes, and patient preference.

Among patients treated with neoadjuvant chemotherapy higher response rates have been seen in those with triple-negative or HER2-positive disease. Therefore, patients with HER2-positive breast cancer are more likely to benefit from neoadjuvant therapy, as well as breast conservation surgery versus mastectomy.


Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.

There is not usually a difference in surgery among patients with differing subtypes of breast cancer, Boughey explains, as most surgical resections are based on the relationship between tumor size and breast size, extent of disease in the lymph nodes, and patient preference.

Among patients treated with neoadjuvant chemotherapy higher response rates have been seen in those with triple-negative or HER2-positive disease. Therefore, patients with HER2-positive breast cancer are more likely to benefit from neoadjuvant therapy, as well as breast conservation surgery versus mastectomy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x